Connect with us

COVID-19

Dr. Peter McCullough Part 1: Thousands of doctors are treating covid. What you need to know to help you stay out of hospital.

Published

3 minute read

For more than a year and a half, Canadians have been struggling to deal with the covid pandemic.  With each wave of cases we’ve been throwing resources, restricting movement and commerce, putting on protectives masks, getting vaccinations, and now pressuring vaccinations on those who are hesitant.  Still, each wave puts even more pressure on the hospitals than the last one.
Considering how many people have become seriously ill, how many people have died, and how much covid has affected our lives in various ways, it’s remarkable our governments haven’t taken the opportunity to examine their approach to battling the virus and all the aspects of society it affects.
There are a few exceptions.  Back in March, the Texas Senate Committee on Health and Human Services called a hearing into how the state had reacted to the pandemic to that time.  One of the presenters was Dr. Peter McCullough.  Dr. McCullough talked about the “near total block” on information about treating covid.   The presentations by Dr. Richard Urso and Dr. Peter McCullough are compelling in that they reveal that across the United States and around the world, thousands of doctors are providing early treatment to covid positive patients with symptoms.  Their data shows astounding success.
Since it seems obvious covid strains will continually appear and stay one step ahead of our vaccines, everyone should know more about the option of early treatment.   The American Association of Physicians and Surgeons represents nearly 5,000 doctors who are treating covid and talking about it.  The association has released a guide for the general public.  Although it’s written for Americans, information about drugs and vitamins that help in the early stages of covid apply everywhere.

In countries around the world, doctors have found that treating COVID patients at home quickly when symptoms develop leads to better outcomes, dramatically lower death rates than if doctors send people home to wait until they are so sick they need hospitalizations, ICU admissions, mechanical ventilators and even dialysis when kidneys fail.

If you’ve been unaware of the extent to which many doctors already know about early treatment the following videos will be incredibly informative.  These videos are exerts from a longer interview by Dr. Alfred Johnson from a medical group in the United States which was published August 20

 

 

There’s another way to end the pandemic. Doctors can knock covid out with treatment

 

Why aren’t more doctors treating covid? Doctor testifies early treatment saves lives

After 15 years as a TV reporter with Global and CBC and as news director of RDTV in Red Deer, Duane set out on his own 2008 as a visual storyteller. During this period, he became fascinated with a burgeoning online world and how it could better serve local communities. This fascination led to Todayville, launched in 2016.

Follow Author

Alberta

New Red Deer City Councillor joins frontline workers in protest against ‘mandatory’ vaccination

Published on

Under imminent threat of losing their jobs, as many as two hundred frontline healthcare workers including paramedics, nurses, and fire fighters gathered in downtown Red Deer Thursday afternoon for a silent protest in front of City Hall Park.  Organizer Kaitlin King, a paramedic from the North Central region says she represents thousands of workers who’ve already had covid and benefit from a very high level of immunity.  Despite her opposition to the covid vaccines, King says she’d be willing to be tested on a regular basis if that was an option.

 

As of Friday afternoon, AHS claims 94% of it’s employees are fully vaccinated.  That number is contested by those who point out the AHS boosted the percentage of vaccinated employees drastically by dropping “casual” employees from their stats.

Whatever the actual number is, AHS has decided it it too high.  Friday, AHS announced via Twitter, that the deadline for AHS employees to be vaccinated or face the loss of their jobs would be delayed from November 1st, to December 1st.

AHS is hoping thousands of employees who’ve decided against the jab so far, will change their minds and begin the process in the coming days.

Meanwhile it appears Vaccine Mandates will be hotly contested by Red Deer’s new City Council.  Newly elected Councillor Victor Doerksen attended the silent rally Thursday.  Doerksen is looking forward to discussing the validity of mandates with his fellow council members as soon as possible.

Continue Reading

COVID-19

Africa tries to end vaccine inequity by replicating its own

Published on

CAPE TOWN, South Africa (AP) — In a pair of Cape Town warehouses converted into a maze of airlocked sterile rooms, young scientists are assembling and calibrating the equipment needed to reverse engineer a coronavirus vaccine that has yet to reach South Africa and most of the world’s poorest people.

The energy in the gleaming labs matches the urgency of their mission to narrow vaccine disparities. By working to replicate Moderna’s COVID-19 shot, the scientists are effectively making an end run around an industry that has vastly prioritized rich countries over poor in both sales and manufacturing.

And they are doing it with unusual backing from the World Health Organization, which is coordinating a vaccine research, training and production hub in South Africa along with a related supply chain for critical raw materials. It’s a last-resort effort to make doses for people going without, and the intellectual property implications are still murky.

“We are doing this for Africa at this moment, and that drives us,” said Emile Hendricks, a 22-year-old biotechnologist for Afrigen Biologics and Vaccines, the company trying to reproduce the Moderna shot. “We can no longer rely on these big superpowers to come in and save us.”

Some experts see reverse engineering — recreating vaccines from fragments of publicly available information — as one of the few remaining ways to redress the power imbalances of the pandemic. Only 0.7% of vaccines have gone to low-income countries so far, while nearly half have gone to wealthy countries, according to an analysis by the People’s Vaccine Alliance.

That WHO, which relies upon the goodwill of wealthy countries and the pharmaceutical industry for its continued existence, is leading the attempt to reproduce a proprietary vaccine demonstrates the depths of the supply disparities.

The U.N.-backed effort to even out global vaccine distribution, known as COVAX, has failed to alleviate dire shortages in poor countries. Donated doses are coming in at a fraction of what is needed to fill the gap. Meanwhile, pressure for drug companies to share, including Biden administration demands on Moderna, has led nowhere.

Until now, WHO has never directly taken part in replicating a novel vaccine for current global use over the objections of the original developers. The Cape Town hub is intended to expand access to the novel messenger RNA technology that Moderna, as well as Pfizer and German partner BioNTech, used in their vaccines.

“This is the first time we’re doing it to this level, because of the urgency and also because of the novelty of this technology,” said Martin Friede, a WHO vaccine research coordinator who is helping direct the hub.

Dr. Tom Frieden, the former head of the U.S. Centers for Disease Control and Prevention, has described the world as “being held hostage” by Moderna and Pfizer, whose vaccines are considered the most effective against COVID-19. The novel mRNA process uses the genetic code for the spike protein of the coronavirus and is thought to trigger a better immune response than traditional vaccines.

Arguing that American taxpayers largely funded Moderna’s vaccine development, the Biden administration has insisted the company must expand production to help supply developing nations. The global shortfall through 2022 is estimated at 500 million and 4 billion doses, depending on how many other vaccines come on the market.

“The United States government has played a very substantial role in making Moderna the company it is,” said David Kessler, the head of Operation Warp Speed, the U.S. program to accelerate COVID-19 vaccine development.

Kessler would not say how far the administration would go in pressing the company. “They understand what we expect to happen,” he said.

Moderna has pledged to build a vaccine factory in Africa at some point in the future. But after pleading with drugmakers to share their recipes, raw materials and technological know-how, some poorer countries are done waiting.

Afrigen Managing Director Petro Terblanche said the Cape Town company is aiming to have a version of the Moderna vaccine ready for testing in people within a year and scaled up for commercial production not long after.

“We have a lot of competition coming from Big Pharma. They don’t want to see us succeed,” Terblanche said. “They are already starting to say that we don’t have the capability to do this. We are going to show them.”

If the team in South Africa succeeds in making a version of Moderna’s vaccine, the information will be publicly released for use by others, Terblanche said. Such sharing is closer to an approach U.S. President Joe Biden championed in the spring and the pharmaceutical industry strongly opposes.

Commercial production is the point at which intellectual property could become an issue. Moderna has said it would not pursue legal action against a company for infringing on its vaccine rights, but neither has it offered to help companies that have volunteered to make its mRNA shot.

Chairman Noubar Afeyan said Moderna determined it would be better to expand production itself than to share technology and plans to deliver billions of additional doses next year.

“Within the next six to nine months, the most reliable way to make high-quality vaccines and in an efficient way is going to be if we make them,” Afeyan said.

Zoltan Kis, an expert in messenger RNA vaccines at Britain’s University of Sheffield, said reproducing Moderna’s vaccine is “doable” but the task would be far easier if the company shared its expertise. Kis estimated the process involves fewer than a dozen major steps. But certain procedures are tricky, such as sealing the fragile messenger RNA in lipid nanoparticles, he said.

“It’s like a very complicated cooking recipe,” he said. “Having the recipe would be very, very helpful, and it would also help if someone could show you how to do it.”

A U.N.-backed public health organization still hopes to persuade Moderna that its approach to providing vaccines for poorer countries misses the mark. Formed in 2010, the Medicines Patent Pool initially focused on convincing pharmaceutical companies to share patents for AIDS drugs.

“It’s not about outsiders helping Africa,” Executive Director Charles Gore said of the South Africa vaccine hub. “Africa wants to be empowered, and that’s what this is about.”

It will eventually fall to Gore to try to resolve the intellectual property question. Work to recreate Moderna’s COVID-19 vaccine is protected as research, so a potential dispute would surround steps to sell a replicated version commercially, he said.

“It’s about persuading Moderna to work with us rather than using other methods,” Gore said.

He said the Medicines Patent Pool repeatedly tried but failed to convince Pfizer and BioNTech to even discuss sharing their formulas.

Rep. Raja Krishnamoorthi, who is among the members of Congress backing a bill that calls on the United States to invest more in making and distributing COVID-19 vaccines in low- and middle-income countries, said reverse engineering isn’t going to happen fast enough to keep the virus from mutating and spreading further.

“We need to show some hustle. We have to show a sense of urgency, and I’m not seeing that urgency,” he said. “Either we end this pandemic or we muddle our way through.”

Campaigners argue the meager amount of vaccines available to poorer countries through donations, COVAX and purchases suggests the Western-dominated pharmaceutical industry is broken.

“The enemy to these corporations is losing their potential profit down the line,” Joia Mukherjee, chief medical officer of the global health nonprofit Partners in Health, said. “The enemy isn’t the virus, the enemy isn’t suffering.”

Back in Cape Town, the promise of using mRNA technology against other diseases motivates the young scientists.

“The excitement is around learning how we harness mRNA technology to develop a COVID-19 vaccine,” Caryn Fenner, Afrigen’s technical director, said. But more important, Fenner said, “is not only using the mRNA platform for COVID, but for beyond COVID.”

___

Cheng reported from London; Hinnant reported from Paris.

Lori Hinnant, Maria Cheng And Andrew Meldrum, The Associated Press

Continue Reading

Trending

X